A Phase 3 Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants with Active Systemic Lupus Erythematosus (POETYK-SLE-2)

Brief description of study

This study is a double-blinded 52-week clinical trial to evaluate the efficacy and safety of deucravacitinib in adult participants with active Systemic Lupus Erythematosus (SLE) while receiving stable background standard of care treatment. The Treatment Period is called a “Double-Blinded” or “Blinded” Treatment Period because neither you nor your study team will know whether you are getting deucravacitinib or placebo. There is a 50% chance of being on deucravacitinib and a 50% chance of being on placebo during this 52-week treatment period.

Clinical Study Identifier: s22-01331
Principal Investigator: David H. Goddard.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.